0.1916
price down icon0.26%   -0.0005
after-market Handel nachbörslich: .20 0.0084 +4.38%
loading
Schlusskurs vom Vortag:
$0.1921
Offen:
$0.181
24-Stunden-Volumen:
818.60K
Relative Volume:
2.74
Marktkapitalisierung:
$7.41M
Einnahmen:
$20.27M
Nettoeinkommen (Verlust:
$-63.80M
KGV:
-0.1261
EPS:
-1.52
Netto-Cashflow:
$-68.35M
1W Leistung:
-41.94%
1M Leistung:
-52.11%
6M Leistung:
-79.72%
1J Leistung:
-90.02%
1-Tages-Spanne:
Value
$0.17
$0.224
1-Wochen-Bereich:
Value
$0.17
$0.37
52-Wochen-Spanne:
Value
$0.17
$2.0497

Carisma Therapeutics Inc Stock (CARM) Company Profile

Name
Firmenname
Carisma Therapeutics Inc
Name
Telefon
(267) 491-6422
Name
Adresse
3675 MARKET STREET, PHILADELPHIA
Name
Mitarbeiter
68
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
CARM's Discussions on Twitter

Vergleichen Sie CARM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CARM
Carisma Therapeutics Inc
0.1916 7.41M 20.27M -63.80M -68.35M -1.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-12 Herabstufung Robert W. Baird Outperform → Neutral
2024-12-10 Herabstufung BTIG Research Buy → Neutral
2024-04-11 Eingeleitet BTIG Research Buy
2023-10-03 Eingeleitet CapitalOne Overweight
2023-07-06 Eingeleitet Evercore ISI Outperform
2023-05-31 Hochstufung Jefferies Hold → Buy
2023-05-24 Eingeleitet H.C. Wainwright Buy
2023-04-14 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Carisma Therapeutics Inc Aktie (CARM) Neueste Nachrichten

pulisher
02:34 AM

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

02:34 AM
pulisher
Apr 03, 2025

Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo

Apr 03, 2025
pulisher
Apr 02, 2025

Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN

Apr 01, 2025
pulisher
Mar 31, 2025

Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Provides Corporate Updates - Citizen Tribune

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st

Mar 28, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World

Mar 28, 2025
pulisher
Mar 22, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World

Mar 22, 2025
pulisher
Mar 13, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com

Mar 13, 2025
pulisher
Feb 25, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Feb 25, 2025
pulisher
Feb 22, 2025

Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN

Feb 22, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow

Feb 19, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow

Feb 19, 2025
pulisher
Feb 11, 2025

Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN

Feb 11, 2025
pulisher
Feb 05, 2025

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow

Feb 05, 2025
pulisher
Feb 04, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World

Feb 04, 2025
pulisher
Jan 31, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 30, 2025
pulisher
Jan 22, 2025

BTIG Downgrades Carisma Therapeutics (CARM) - MSN

Jan 22, 2025
pulisher
Jan 18, 2025

Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 18, 2025
pulisher
Jan 14, 2025

Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 14, 2025
pulisher
Jan 11, 2025

Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India

Jan 11, 2025
pulisher
Jan 10, 2025

Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 06, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 03, 2025
pulisher
Dec 30, 2024

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com

Dec 30, 2024
pulisher
Dec 27, 2024

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow

Dec 27, 2024
pulisher
Dec 26, 2024

Carisma Therapeutics Appoints Interim VP of Finance - TipRanks

Dec 26, 2024
pulisher
Dec 20, 2024

Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN

Dec 20, 2024
pulisher
Dec 18, 2024

Carisma downgraded by H.C. Wainwright to neutral - MSN

Dec 18, 2024
pulisher
Dec 17, 2024

Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World

Dec 17, 2024
pulisher
Dec 16, 2024

HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

Carisma shares downgraded to neutral after program halt - Investing.com

Dec 16, 2024

Finanzdaten der Carisma Therapeutics Inc-Aktie (CARM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):